FDA plans significant increase of GMP Inspections in China
Recommendation
12-14 November 2024
Barcelona, Spain
Data Governance and Auditing the Analytical Process from Sampling to Reportable Value
For quite some time, the US FDA has elaborated concrete plans to increase the number of inspections in China. These plans were developed as a
consequence of the Heparin crisis. Already in 2008, the US FDA opened offices in China to increase the number of GMP Inspections. However, little progress has been made since that time.In parallel, the US FDA has identified some major problems with pharmaceutical and API manufacturers in India. A number of Warning Letters addressed to Indian companies have been published. More seriously, the inspections findings which caused the Warning Letters did not only contain GMP deviations but also cases of fraud and falsification of data.
There are concerns that a lack of supervision might have caused similar non-compliance situations in China as well. Yet, without a comprehensive inspection programme in place there is no proven evidence for such a concern. The website
Pharmalot has just recently reported about the problems which caused the delay in performing more inspections: China has refused to issue visa for FDA staff. This issue has now been solved.The
US White House has published a statement on December 5th about a new agreement with China. According to a new Pharmalot article, the US FDA will now increase its inspection activities.Related GMP News
23.10.2024Root Cause Analysis: What can be found in FDA Warning Letters?
23.10.2024Do you want to host FDA Staff? FDA announces Experiential Learning Site Visit Program
09.10.2024Management circumvents Quality Department in Deviation Classification - FDA Warning Letter
09.10.2024Despite MRA: Why does the FDA inspect so frequently in the EU?
02.10.2024Swissmedic launched own GMDP Database
18.09.2024Large Number of Deficiencies at Indian Manufacturer leads to Warning Letter